SanegeneBio struck licensing agreements with Roche/Genentech for an RNAi program that include a $200 million upfront payment and potential for up to roughly $1.5–1.7 billion in development and commercialization milestones. Sanegene will handle early development while Genentech will lead later clinical work and global commercialization under the terms disclosed. Sanegene CEO Weimin Wang framed the transaction as validation of the company’s RNAi chemistry and delivery platforms. The deals follow recent industry interest in tissue‑targeted RNA therapeutics and come as large pharma re‑engages with RNA approaches. The arrangement underscores Big Pharma’s appetite to partner for modality expertise while outsourcing early development risk to specialized biotechs.